Literature DB >> 23794682

Evolution of mild cognitive impairment in Parkinson disease.

M Broeders1, R M A de Bie, D C Velseboer, J D Speelman, D Muslimovic, B Schmand.   

Abstract

OBJECTIVE: We examined the development of Parkinson disease (PD)-mild cognitive impairment (MCI) in patients with newly diagnosed PD over 5 years using recently proposed consensus criteria, and we assessed the reliability of the criteria.
METHODS: Patients with PD (n = 123) underwent extensive neuropsychological testing at baseline and after 3 (n = 93) and 5 years (n = 59). Two neuropsychologists independently applied the PD-MCI criteria to examine the interrater and intrarater reliability.
RESULTS: At baseline, 35% of patients had PD-MCI. Three years later, 53% of the patients had PD-MCI. At 5-year follow-up, 20 patients who had PD-MCI at an earlier assessment had converted to PD dementia and 50% of the remaining patients without dementia had MCI. The interrater reliability (kappa) was 0.91. The intrarater reliabilities were 0.85 and 0.96.
CONCLUSION: Approximately one-third of patients with newly diagnosed PD fulfill the consensus criteria for PD-MCI; after 5 years, this proportion is approximately 50% of patients without dementia. The criteria have good interrater and intrarater reliability.

Entities:  

Mesh:

Year:  2013        PMID: 23794682     DOI: 10.1212/WNL.0b013e31829c5c86

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 2.  Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.

Authors:  Katherine Leaver; Kathleen L Poston
Journal:  Neuropsychol Rev       Date:  2015-12-01       Impact factor: 7.444

3.  Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Authors:  Taylor R Hendershott; Delphine Zhu; Seoni Llanes; Cyrus P Zabetian; Joseph Quinn; Karen L Edwards; James B Leverenz; Thomas Montine; Brenna Cholerton; Kathleen L Poston
Journal:  Mov Disord       Date:  2018-12-10       Impact factor: 10.338

Review 4.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

5.  Course of psychiatric symptoms and global cognition in early Parkinson disease.

Authors:  Patricia de la Riva; Kara Smith; Sharon X Xie; Daniel Weintraub
Journal:  Neurology       Date:  2014-08-15       Impact factor: 9.910

Review 6.  Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Authors:  Jamie Eberling; Lona Vincent; Jennifer G Goldman; Daniel Weintraub; Jaime Kulisevsky; Connie Marras; Glenn Stebbins; Karl Kieburtz
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

7.  Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

Authors:  Rafael González-Redondo; David García-García; Pedro Clavero; Carmen Gasca-Salas; Reyes García-Eulate; José L Zubieta; Javier Arbizu; José A Obeso; María C Rodríguez-Oroz
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

8.  Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients.

Authors:  Aristide Merola; Laura Rizzi; Carlo Alberto Artusi; Maurizio Zibetti; Mario Giorgio Rizzone; Alberto Romagnolo; Andrea Bernardini; Michele Lanotte; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

Review 9.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  Initial cognitive changes in Parkinson's disease.

Authors:  Daniel Weintraub; Alexander I Tröster; Connie Marras; Glenn Stebbins
Journal:  Mov Disord       Date:  2018-03-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.